<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Reactive oxygen species play a role in the response of brain to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The effects of <z:chebi fb="0" ids="25216">metalloporphyrin</z:chebi> catalytic <z:chebi fb="11" ids="22586">antioxidants</z:chebi> (AEOL 10113 and AEOL 10150) were examined after murine middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="2" pm="."><plain>Ninety minutes after reperfusion from 90 min MCAO in the rat, AEOL 10113, AEOL 10150, or vehicle were given intracerebroventricularly </plain></SENT>
<SENT sid="3" pm="."><plain>AEOL 10113 and AEOL 10150 similarly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size (35%) and neurologic deficit </plain></SENT>
<SENT sid="4" pm="."><plain>AEOL 10113 caused behavioral side effects at twice the neuroprotective dose while AEOL 10150 required a 15-fold increase from the neuroprotective dose to cause <z:hpo ids='HP_0000708'>behavioral changes</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>AEOL 10150, given 6 h after 90 min MCAO, reduced total <z:mpath ids='MPATH_124'>infarct</z:mpath> size by 43% without temperature effects </plain></SENT>
<SENT sid="6" pm="."><plain>Brain AEOL 10150 elimination t(1/2) was 10 h </plain></SENT>
<SENT sid="7" pm="."><plain>In the mouse, intravenous AEOL 10150 infusion post-MCAO reduced both <z:mpath ids='MPATH_124'>infarct</z:mpath> size (25%) and neurologic deficit </plain></SENT>
<SENT sid="8" pm="."><plain>Brain AEOL 10150 uptake, greater in the ischemic hemisphere, was dose- and time-dependent </plain></SENT>
<SENT sid="9" pm="."><plain>AEOL 10150 had direct effects on proteomic events and ameliorated changes caused by <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>In primary mixed neuronal/glial cultures exposed to 2 h of <z:chebi fb="0" ids="15379">O(2)</z:chebi>/<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation, AEOL 10150 reduced <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase release dose-dependently and selectively preserved aconitase activity in concentrations consistent with neuroprotection in vivo </plain></SENT>
<SENT sid="11" pm="."><plain>AEOL 10150 is an effective neuroprotective compound offering a wide therapeutic window with a large margin of safety against adverse behavioral side effects </plain></SENT>
</text></document>